Level C· Early human research exploring benefitsProspective StudyPubMed

Injection of the Concentrate Derived from Nanofat Graft Promotes Hair Growth in Patients of Male Androgenetic Alopecia: A Clinical Pilot Study.

Zhang Z., Chen N., Xiao L., Li K., Liu H.

Prospective Study on Hair Loss, Hair Regeneration, published in Aesthetic Plast Surg (2025) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Aesthetic Plast Surg (2025)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
41028613
DOI
10.1007/s00266-025-05291-z
Citations
1

Abstract (original English)

Background Androgenetic alopecia (AGA) is the most common hair loss disorder in men. Adipose-derived stem cells (ADSCs) have shown regenerative potential, but their clinical application is hindered by complex processing. Concentrate derived from nanofat graft (CDNF), rich in ADSCs, promotes hair growth in mice, suggesting its potential clinical efficacy. Objective This study aimed to assess the efficacy of intradermal CDNF injection as a novel autologous therapeutic approach for AGA. Methods Ten male AGA patients (Norwood-Hamilton III-VI, aged 22-38) received three CDNF injections (0.25ml/cm 2 ) into the scalp subdermis at 4-week intervals. Changes in hair density, diameter, and pigmentation were evaluated via ultra-high-resolution photography at baseline, 3, 6, and 12 months post-treatment. Results All patients exhibited hair regeneration at all follow-ups. Significant improvements were observed not only in total hair count but also in hair diameter and pigmentation. Quantitative analysis revealed a significant increase in the number of hairs with a diameter >0.03 mm at all follow-up time points. Conversely, the number of hairs with a diameter ≤0.03 mm demonstrated a notable decrease at the 3- and 6-month assessments. Peak efficacy was observed at 12 months post-injection, with total hair counts significantly exceeding baseline levels. No severe adverse events were reported. F

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
HumansMaleAlopeciaPilot ProjectsAdultInjections, IntradermalTreatment OutcomeYoung AdultHairAdipose Tissue

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research